Results 191 to 200 of about 28,807 (265)

Absence of Interaction Between 5α‐Reductase Inhibitors and Glucocorticoids on Incidence of Myocardial Infarction in People With Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims People with Type 2 diabetes experience higher cardiometabolic risk, and both synthetic glucocorticoids and use of 5α‐reductase inhibitors have been individually linked to increased risk of myocardial infarction. We tested whether the increase in risk is exacerbated by co‐prescription of both drugs.
Haolan Tu   +20 more
wiley   +1 more source

Hypercortisolism: An Under‐Recognised Pathway Linked to Multi‐System Complications

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT The clinical understanding of hypercortisolism (HC) has evolved from a classic overt syndrome with florid Cushingoid features to a broader spectrum of disease that includes milder presentations, often referred to as mild autonomous cortisol secretion (MACS).
Hernan Daniel Sacoto, Vivian A. Fonseca
wiley   +1 more source

Is Hypercortisolism Treatable? Which Patients Should Be Treated and How—A Practical Guide for Clinicians

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim To provide a practical guide on when to suspect endogenous hypercortisolism, how to use the overnight 1‐mg dexamethasone suppression test (DST) for targeted case‐finding, and which patients are most likely to benefit from treatment.
Juan Pablo Frias
wiley   +1 more source

Home - About - Disclaimer - Privacy